CytomX Therapeutics (CTMX) Stock Forecast, Price Target & Predictions
CTMX Stock Forecast
CytomX Therapeutics stock forecast is as follows: an average price target of $5.77 (represents a 369.11% upside from CTMX’s last price of $1.23) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
CTMX Price Target
CTMX Analyst Ratings
CytomX Therapeutics Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Aug 09, 2024 | Etzer Darout | BMO Capital | $3.56 | $1.18 | 201.69% | 189.43% |
May 27, 2024 | Joseph Catanzaro | Piper Sandler | $3.50 | $1.75 | 100.00% | 184.55% |
May 09, 2024 | Etzer Darout | BMO Capital | $3.59 | $4.19 | -14.32% | 191.87% |
May 09, 2024 | Robert Driscoll | Wedbush | $8.00 | $2.40 | 233.46% | 550.41% |
May 05, 2024 | Roger Song | Jefferies | $8.00 | $4.46 | 79.57% | 550.41% |
Mar 12, 2024 | Roger Song | Jefferies | $2.50 | $2.15 | 16.28% | 103.25% |
Mar 12, 2024 | Etzer Darout | BMO Capital | $3.25 | $2.15 | 51.16% | 164.23% |
Jan 06, 2023 | - | BMO Capital | $3.20 | $1.79 | 78.77% | 160.16% |
Nov 14, 2022 | - | BMO Capital | $2.60 | $1.29 | 101.55% | 111.38% |
CytomX Therapeutics Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | 1 | 7 |
Avg Price Target | - | $3.56 | $4.63 |
Last Closing Price | $1.23 | $1.23 | $1.23 |
Upside/Downside | -100.00% | 189.43% | 276.42% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Sep 13, 2024 | H.C. Wainwright | Neutral | Neutral | Hold |
Aug 09, 2024 | BMO Capital | Market Perform | Market Perform | Hold |
Jun 27, 2024 | H.C. Wainwright | Neutral | Neutral | Hold |
May 27, 2024 | Piper Sandler | Neutral | Overweight | Upgrade |
May 09, 2024 | H.C. Wainwright | Neutral | Neutral | Hold |
May 09, 2024 | BMO Capital | Market Perform | Market Perform | Hold |
May 05, 2024 | Jefferies | - | Buy | Upgrade |
Nov 08, 2023 | Wedbush | - | Outperform | Upgrade |
Jan 06, 2023 | BMO Capital | Market Perform | Market Perform | Hold |
Nov 14, 2022 | BMO Capital | - | Market Perform | Downgrade |
CytomX Therapeutics Financial Forecast
CytomX Therapeutics Revenue Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $26.61M | $26.38M | $24.72M | $23.50M | $946.00K | $16.91M | - | $17.14M | $19.73M | $17.59M | $16.29M | $15.97M | $16.37M | $17.79M | $16.61M | $49.59M | $8.28M | $10.71M |
Avg Forecast | $46.26M | $43.52M | $40.94M | $38.51M | $10.38M | $18.64M | $18.39M | $18.89M | $14.27M | $17.10M | $20.00M | $19.35M | $19.60M | $13.34M | $13.68M | $19.91M | $18.07M | $18.15M | $18.11M | $21.25M | $19.57M | $18.38M | $16.96M | $18.28M | $16.09M | $17.14M | $52.99M | $20.98M | $17.37M | $18.07M |
High Forecast | $66.31M | $62.38M | $58.68M | $55.21M | $14.87M | $26.72M | $26.36M | $27.08M | $20.45M | $22.69M | $28.67M | $27.74M | $26.09M | $19.13M | $19.61M | $28.54M | $25.91M | $26.02M | $18.11M | $26.53M | $24.44M | $22.96M | $21.18M | $22.83M | $20.09M | $21.40M | $66.17M | $26.20M | $21.69M | $22.56M |
Low Forecast | $21.13M | $19.88M | $18.70M | $17.60M | $4.74M | $8.52M | $8.40M | $8.63M | $6.52M | $10.85M | $9.14M | $8.84M | $12.58M | $6.10M | $6.25M | $9.10M | $8.26M | $8.29M | $18.11M | $11.55M | $10.64M | $9.99M | $9.22M | $9.94M | $8.74M | $9.31M | $28.80M | $11.40M | $9.44M | $9.82M |
# Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 2 | 3 | 4 | 8 | 5 | 3 | 3 | 3 | 3 | 3 | 2 | 3 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.36% | 1.98% | 1.81% | 1.18% | 0.05% | 0.93% | - | 0.81% | 1.01% | 0.96% | 0.96% | 0.87% | 1.02% | 1.04% | 0.31% | 2.36% | 0.48% | 0.59% |
CytomX Therapeutics EBITDA Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 2 | 3 | 4 | 8 | 5 | 3 | 3 | 3 | 3 | 3 | 2 | 3 |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-120.00K | $3.12M | $-2.74M | $-5.06M | $-28.08M | $-23.32M | - | $-23.36M | $-25.55M | $-21.90M | $-18.57M | $-14.88M | $-14.04M | $-14.06M | $-15.06M | $-1.07M | $-35.27M | $-23.02M |
Avg Forecast | $-32.39M | $-30.47M | $-28.67M | $-26.97M | $-7.27M | $-13.05M | $-12.88M | $-13.23M | $-9.99M | $-11.97M | $-14.00M | $-31.41M | $-13.72M | $-9.34M | $-9.58M | $-28.55M | $-12.66M | $-20.08M | $-12.68M | $-22.57M | $-13.71M | $-18.25M | $-15.71M | $-18.71M | $-19.09M | $-18.74M | $-55.90M | $-2.47M | $-28.68M | $-22.57M |
High Forecast | $-14.80M | $-13.92M | $-13.10M | $-12.32M | $-3.32M | $-5.96M | $-5.88M | $-6.04M | $-4.56M | $-7.59M | $-6.40M | $-25.13M | $-8.81M | $-4.27M | $-4.38M | $-22.84M | $-5.78M | $-16.06M | $-12.68M | $-18.06M | $-7.45M | $-14.60M | $-12.57M | $-14.97M | $-15.27M | $-15.00M | $-44.72M | $-1.97M | $-22.94M | $-18.06M |
Low Forecast | $-46.43M | $-43.68M | $-41.09M | $-38.66M | $-10.41M | $-18.71M | $-18.46M | $-18.96M | $-14.32M | $-15.89M | $-20.08M | $-37.69M | $-18.27M | $-13.40M | $-13.73M | $-34.26M | $-18.14M | $-24.09M | $-12.68M | $-27.08M | $-17.12M | $-21.90M | $-18.85M | $-22.45M | $-22.91M | $-22.49M | $-67.08M | $-2.96M | $-34.41M | $-27.08M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.01% | -0.33% | 0.29% | 0.18% | 2.22% | 1.16% | - | 1.04% | 1.86% | 1.20% | 1.18% | 0.80% | 0.74% | 0.75% | 0.27% | 0.43% | 1.23% | 1.02% |
CytomX Therapeutics Net Income Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 2 | 3 | 4 | 8 | 5 | 3 | 3 | 3 | 3 | 3 | 2 | 3 |
Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $837.00K | $2.99M | $-1.09M | $-969.00K | $-26.58M | $-22.65M | - | $-23.80M | $-26.23M | $-22.58M | $-19.24M | $-15.55M | $-14.70M | $-14.71M | $-15.68M | $12.21M | $-35.46M | $-23.70M |
Avg Forecast | $-25.08M | $-24.45M | $-23.96M | $-24.06M | $-18.92M | $-11.62M | $-12.78M | $-11.58M | $-18.62M | $-14.63M | $-8.47M | $-32.31M | $-4.10M | $-16.01M | $-16.05M | $-29.38M | $-19.99M | $-20.70M | $-30.84M | $-23.22M | $-23.31M | $-18.82M | $-16.28M | $-19.55M | $-19.99M | $-19.61M | $-58.21M | $28.18M | $-28.83M | $-23.23M |
High Forecast | $-7.37M | $-7.19M | $-7.04M | $-7.07M | $-5.56M | $-3.42M | $-3.76M | $-3.40M | $-5.47M | $10.97M | $-2.49M | $-25.85M | $16.39M | $-4.71M | $-4.72M | $-23.50M | $-5.88M | $-16.56M | $-30.84M | $-18.58M | $-9.48M | $-15.06M | $-13.03M | $-15.64M | $-15.99M | $-15.69M | $-46.57M | $33.81M | $-23.06M | $-18.59M |
Low Forecast | $-39.22M | $-38.23M | $-37.46M | $-37.61M | $-29.58M | $-18.17M | $-19.98M | $-18.10M | $-29.10M | $-29.25M | $-13.24M | $-38.78M | $-24.59M | $-25.03M | $-25.09M | $-35.25M | $-31.26M | $-24.84M | $-30.84M | $-27.87M | $-30.85M | $-22.58M | $-19.54M | $-23.46M | $-23.99M | $-23.54M | $-69.85M | $22.54M | $-34.60M | $-27.88M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -0.20% | -0.19% | 0.07% | 0.03% | 1.33% | 1.09% | - | 1.03% | 1.13% | 1.20% | 1.18% | 0.80% | 0.74% | 0.75% | 0.27% | 0.43% | 1.23% | 1.02% |
CytomX Therapeutics SG&A Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 2 | 3 | 4 | 8 | 5 | 3 | 3 | 3 | 3 | 3 | 2 | 3 |
SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $7.79M | $6.81M | $7.40M | $7.98M | $10.07M | $10.49M | - | $10.54M | $9.46M | $11.09M | $9.39M | $9.23M | $9.14M | $8.63M | $8.68M | $9.57M | $9.22M | $8.46M |
Avg Forecast | $24.63M | $23.17M | $21.80M | $20.51M | $5.52M | $9.93M | $9.79M | $10.06M | $7.60M | $9.11M | $10.65M | $14.26M | $10.44M | $7.11M | $7.28M | $12.97M | $9.62M | $10.16M | $9.65M | $10.25M | $10.42M | $9.24M | $7.95M | $11.60M | $12.44M | $11.51M | $32.22M | $11.17M | $7.49M | $8.30M |
High Forecast | $35.31M | $33.22M | $31.25M | $29.40M | $7.92M | $14.23M | $14.04M | $14.42M | $10.89M | $12.08M | $15.27M | $17.12M | $13.89M | $10.19M | $10.44M | $15.56M | $13.80M | $12.19M | $9.65M | $12.30M | $13.02M | $11.09M | $9.54M | $13.92M | $14.92M | $13.81M | $38.67M | $13.95M | $8.99M | $9.96M |
Low Forecast | $11.25M | $10.59M | $9.96M | $9.37M | $2.52M | $4.54M | $4.47M | $4.60M | $3.47M | $5.78M | $4.87M | $11.41M | $6.70M | $3.25M | $3.33M | $10.37M | $4.40M | $8.13M | $9.65M | $8.20M | $5.66M | $7.39M | $6.36M | $9.28M | $9.95M | $9.21M | $25.78M | $6.07M | $6.00M | $6.64M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.75% | 0.96% | 1.02% | 0.62% | 1.05% | 1.03% | - | 1.03% | 0.91% | 1.20% | 1.18% | 0.80% | 0.74% | 0.75% | 0.27% | 0.86% | 1.23% | 1.02% |
CytomX Therapeutics EPS Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 2 | 3 | 4 | 8 | 5 | 3 | 3 | 3 | 3 | 3 | 2 | 3 |
EPS | - | - | - | - | - | - | - | - | - | - | - | - | $0.01 | $0.04 | $-0.02 | $-0.01 | $-0.40 | $-0.34 | - | $-0.36 | $-0.40 | $-0.35 | $-0.30 | $-0.26 | $-0.32 | $-0.32 | $-0.34 | $0.27 | $-0.78 | $-0.52 |
Avg Forecast | $-0.30 | $-0.29 | $-0.28 | $-0.28 | $-0.22 | $-0.14 | $-0.15 | $-0.14 | $-0.22 | $-0.17 | $-0.10 | $-0.10 | $-0.05 | $-0.19 | $-0.19 | $-0.11 | $-0.24 | $-0.30 | $-0.37 | $-0.36 | $-0.35 | $-0.31 | $-0.32 | $-0.35 | $-0.50 | $-0.48 | $0.16 | $-0.45 | $-0.47 | $-0.52 |
High Forecast | $-0.09 | $-0.08 | $-0.08 | $-0.08 | $-0.07 | $-0.04 | $-0.04 | $-0.04 | $-0.06 | $0.13 | $-0.03 | $-0.03 | $0.19 | $-0.06 | $-0.06 | $-0.03 | $-0.07 | $-0.09 | $-0.37 | $-0.15 | $-0.14 | $-0.13 | $-0.13 | $-0.14 | $-0.20 | $-0.19 | $0.21 | $-0.18 | $-0.19 | $-0.21 |
Low Forecast | $-0.46 | $-0.45 | $-0.44 | $-0.44 | $-0.35 | $-0.21 | $-0.24 | $-0.21 | $-0.34 | $-0.34 | $-0.16 | $-0.16 | $-0.29 | $-0.29 | $-0.30 | $-0.17 | $-0.37 | $-0.48 | $-0.37 | $-0.47 | $-0.46 | $-0.41 | $-0.42 | $-0.46 | $-0.67 | $-0.63 | $0.06 | $-0.59 | $-0.62 | $-0.69 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -0.26% | -0.20% | 0.09% | 0.13% | 1.70% | 1.12% | - | 1.01% | 1.15% | 1.12% | 0.94% | 0.75% | 0.63% | 0.67% | -2.17% | -0.61% | 1.65% | 0.99% |
CytomX Therapeutics Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
SPRO | Spero Therapeutics | $1.37 | $10.00 | 629.93% | Buy |
CTMX | CytomX Therapeutics | $1.23 | $5.77 | 369.11% | Buy |
ACHL | Achilles Therapeutics | $0.72 | $2.00 | 177.78% | Buy |
NUVB | Nuvation Bio | $3.05 | $7.00 | 129.51% | Buy |
NXTC | NextCure | $1.40 | $3.00 | 114.29% | Buy |
TIL | Instil Bio | $84.52 | $17.67 | -79.09% | Hold |
CTMX Forecast FAQ
Is CytomX Therapeutics a good buy?
Yes, according to 5 Wall Street analysts, CytomX Therapeutics (CTMX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 60.00% of CTMX's total ratings.
What is CTMX's price target?
CytomX Therapeutics (CTMX) average price target is $5.77 with a range of $3.5 to $8, implying a 369.11% from its last price of $1.23. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will CytomX Therapeutics stock go up soon?
According to Wall Street analysts' prediction for CTMX stock, the company can go up by 369.11% (from the last price of $1.23 to the average price target of $5.77), up by 550.41% based on the highest stock price target, and up by 184.55% based on the lowest stock price target.
Can CytomX Therapeutics stock reach $2?
CTMX's average twelve months analyst stock price target of $5.77 supports the claim that CytomX Therapeutics can reach $2 in the near future.
What are CytomX Therapeutics's analysts' financial forecasts?
CytomX Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $66.3M (high $95.04M, low $30.29M), average EBITDA is $-46.426M (high $-21.211M, low $-66.55M), average net income is $-54.902M (high $-16.138M, low $-85.84M), average SG&A $35.3M (high $50.61M, low $16.13M), and average EPS is $-0.647 (high $-0.19, low $-1.011). CTMX's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $169.23M (high $242.58M, low $77.32M), average EBITDA is $-119M (high $-54.141M, low $-170M), average net income is $-97.553M (high $-28.675M, low $-153M), average SG&A $90.11M (high $129.18M, low $41.17M), and average EPS is $-1.149 (high $-0.338, low $-1.797).
Did the CTMX's actual financial results beat the analysts' financial forecasts?
Based on CytomX Therapeutics's last annual report (Dec 2023), the company's revenue was $101.21M, beating the average analysts forecast of $66.53M by 52.12%. Apple's EBITDA was $-6.484M, missing the average prediction of $-61.199M by -89.41%. The company's net income was $-569K, missing the average estimation of $-65.53M by -99.13%. Apple's SG&A was $30.02M, missing the average forecast of $37.79M by -20.57%. Lastly, the company's EPS was $0, missing the average prediction of $-0.537 by -100.00%. In terms of the last quarterly report (Dec 2023), CytomX Therapeutics's revenue was $26.61M, beating the average analysts' forecast of $19.6M by 35.76%. The company's EBITDA was $-120K, missing the average prediction of $-13.724M by -99.13%. CytomX Therapeutics's net income was $837K, missing the average estimation of $-4.099M by -120.42%. The company's SG&A was $7.79M, missing the average forecast of $10.44M by -25.36%. Lastly, the company's EPS was $0.0124, missing the average prediction of $-0.0483 by -125.68%